Home > Shop All Products >


Alternative Views:

There are many blood pressure products on the market, but how many of them are backed by human clinical trials?
  • Utilizes AmealPeptide®, a lactotripeptide supplement.
  • Helps support healthy cardiovascular function.
  • Helps maintain healthy blood vessel tone, allowing blood to flow more easily.
  • Helps maintain healthy blood pressure levels.
  • Has shown a comparable effect to (if not better than) most standard ACE Inhibitors.
  • No observable side effects, at doses up to 28 grams per day.
Prices Starting At: $19.99


30 Capsules

  • AmealPeptide®, featured in TriPeptide-2X®, is one of the few ingredients that has repeatedly proven its efficacy. In fact, several published human studies have shown that AmealPeptide® helps maintain both systolic & diastolic blood pressure levels already within a healthy range.*
  • AmealPeptide® is produced from milk protein through a proprietary fermentation and enzymatic process that releases very small proteins called tripeptides, making them available to the body.
  • AmealPeptide® consists of two tripeptides – VPP & IPP – that work by blocking an enzyme to help promote normal blood flow.*

How Lactotripeptides work

TriPeptide-2X® utilizes
AmealPeptide®, a lactotripeptide supplement that helps support healthy cardiovascular function and helps maintain healthy blood vessel tone, allowing blood to flow more easily. When taken with a healthy diet and regular exercise, TriPeptide-2X® can help you maintain healthy blood pressure levels. In studies, AmealPeptide® has a comparable effect to (if not better than) most standard ACE Inhibitors. Without any observable side effects, at doses up to 28 grams per day.

Approximate blood pressure reductions observed after 8 weeks of treatment with AmealPeptide® in individuals with mild-to-moderate hypertension were 12-15 mm Hg SBP and 7 mm Hg DBP. The blood pressure lowering benefits of AmealPeptide® extended beyond the trial periods.
Following AmealPeptide® discontinuation, participants experienced sustained reductions and a gradual return to baseline values within 2-8 weeks.

These lactotripeptides sequences in
TriPeptide-2X® exist naturally in casein. Lactotripeptides have been used in Japan for BP since 1997 and in the U.S.A since 2003.

How TriPeptide-2X® Works:

Biochemical reactions in your body can cause your blood vessels to narrow, making your blood pressure rise. AmealPeptide®, the naturally-derived, key ingredient in TriPeptide-2X®, blocks these reactions so your blood pressure is maintained at a healthy level.*

The Key Ingredient AmealPeptide ® is the proprietary name for the two lactotripeptide Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline (IPP). Clinical studies have shown that it requires the combination of both VPP and IPP to produce optimal benefits for your blood pressure.

AmealPeptide® is derived from casein, which is a milk protein that is also found in dairy products. However, it is difficult to eat enough of these dairy products on a daily basis to obtain the blood pressure benefit that you can get from AmealPeptide®. Calpis' proprietary enzymatic technology hydrolyzes the milk protein to unlock the lactotripeptide (AmealPeptide®) responsible for helping you maintain healthy blood pressure.*

Since it is purified and contains no lactose, AmealPeptide® is safe for people who are lactose intolerant or have milk allergies.

Take TriPeptide-2X® daily and for the full 30 days for optimum benefits. Numerous studies have shown no adverse effects. Talk to your doctor to see if TriPeptide-2X® is right for you.

AlchePharma Tripeptide-2X from AlchePharma on Vimeo.

Further in Depth Description

Origins of the name “AmealPeptide

AmealPeptide® is also known as Lactotripeptides. It was named derived from Mongolian words, “ami” meaning life, and “amil” meaning to revive, recover, and fermentate.

® was discovered over the course of around 40 years of continuous research into the physiological functions of fermented milk, produced during the process of manufacturing the lactic acid drink CALPIS®.

Key features include its blood pressure-lowering effects and ability to improve cardiovascular functions. AmealPeptide
® has an inhibitory activity against angiotensin converting enzyme(ACE). It works on blood vessels by inhibiting enzymes that cause elevated blood pressure, thereby minimizing increases in blood pressure, and by stimulating production of nitric oxide (NO), which helps to protect blood vessels.

Lactotripeptides (AmealPeptide
®) is certified as a “food for specified health use” (FOSHU) in Japan and has been granted GRAS approval in the US.

is an Informed-Choice and Informed-Sport certified raw material and each batch undergoes banned substance testing, which reassures elite athletes and drug tested consumers that the AmealPeptide ingredient does not lead to failed anti-doping tests.

Lactotripeptides prevent blood pressure from rising by inhibiting enzymes that cause elevated blood pressure.

Mechanism to Make Blood Vessels More Flexible

Lactotripeptides have an effect on blood vessels by stimulating production of substances with vascular protective effects.

The vascular endothelial cells on the inside of blood vessels release factors that regulate blood vessel functions, thereby ensuring that your blood vessels stay healthy. One of the factors that the endothelial cells release is Nitric Oxide (NO).

NO causes blood vessels to dilate, and also has the effect of preventing white blood cells from adhering to blood vessel walls and building up to form deposits. Lactotripeptides stimulate production of NO by vascular endothelial cells, which makes blood vessels more flexible.

History of Lactotripeptides research and development




Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials

Milk-based dietary supplement produces significant results

New Orleans, LA, May 16 - Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide® reduces blood pressure in hypertensive patients. The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide® Dietary Supplement ) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study confirmed the safety and efficacy of AmealPeptide® for patients with Stage I and Stage II hypertension.

The AHEAD II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6 mmHg for the active group after 6 weeks of treatment. The change was both statistically and clinically significant. According to JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), just a 2 mmHg reduction in systolic blood pressure results in a 6% reduction in mortality due to stroke and a 4% reduction in mortality due to coronary heart disease (CHD).

Results of the PROBE study showed AmealPeptide® to have a dose dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6 mmHg (± 8.7) in the 75 mg a day group and also a significant reduction in 24-hr systolic blood pressure in the same group of 6.2 mmHg (± 8.4) from the baseline after 8 weeks of treatment. A lower dose of 5 mg a day of AmealPeptide® also showed blood pressure lowering effect.

"It's very exciting to see blood pressure reductions achieved by the food derived substance, AmealPeptide®" stated Joel Neutel, MD, Associate Clinical Professor of Medicine at the University of California, Irvine and a specialist in clinical hypertension of the American Society of Hypertension. "With hypertension and prehypertension on the rise, physicians and patients need as many effective tools as possible for the management of this condition," he concluded.

The AHEAD II study enrolled 81 newly diagnosed stage I and stage II hypertensives. All subjects had a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. Fifty-two received 75 mg of AmealPeptide® twice a day for 6 weeks, while 29 received a placebo. The PROBE study enrolled 59 diagnosed stage I and stage II hypertensives who were not taking any antihypertensive medications or who were uncontrolled on antihypertensive therapy. All subjects had a mean seated systolic blood pressure between 150 mmHg and 179 mmHg and a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. All enrolled received AmealPeptide® (5mg, 15mg, 50mg, 75mg a day or 75mg twice a day) or placebo.

"Calpis takes pride in conducting research that holds up under serious scientific scrutiny," said Craig Tillman, Vice President of Sales & Marketing, Calpis USA, Inc. "This new data confirms that AmealPeptide® can make a difference in those with elevated blood pressure."

The AHEAD II and PROBE data builds on more than 11 previous Japanese placebo-controlled clinical studies showing that AmealPeptide® lowers blood pressure in hypertensives and prehypertensives without producing the side effects that can be associated with drug therapy.

About AmealPeptide®

AmealPeptide® is derived from the milk protein casein and consists of two tripeptides -- Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) -- that has been shown to have angiotensin converting enzyme (ACE) inhibitory characteristics. These peptide sequences exist naturally in casein. However, they are not released in the gut by the action of digestive enzymes. They are released by propriety fermentation and enzymatic processes developed by Calpis Co., Ltd.

About Calpis

Since 1917, Calpis Co., Ltd. has manufactured and sold fermented and cultured milk-based products. Calpis' innovative microbiological technology is in the forefront of scientific achievement in lactic-acid fermentation processing, and has secured its leading position in the global marketplace. Calpis is the first and only company to isolate AmealPeptide®, which has been shown to safely lower blood pressure in 13 published, scientific clinical studies. It recently introduced ameal bp®, a dietary supplement containing AmealPeptide®, in the U.S. market. Calpis is well known in Asia as a soft drink brand, and in recent years its AmealPeptide®-based health drinks and dietary supplements have made their mark on the burgeoning functional foods market in Japan, Europe and the U.S. For more information visit www.calpis.net.

About ASH

The American Society of Hypertension, Inc. (ASH) is the largest US organization devoted exclusively to hypertension and related cardiovascular diseases. ASH is committed to alerting physicians, allied health professionals and the public about new medical options, facts, research findings and treatment choices designed to reduce the risk of cardiovascular disease. For more information, visit www.ash-us.org.

Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects.



Lactobacillus helveticus LBK-16H-fermented milk products containing tripeptides isoleucine-proline-proline and valine-proline-proline lower blood pressure in hypertensive subjects using office and home blood pressure registration. The present study was aimed to evaluate the effects of two doses of these lactotripeptides on 24-h ambulatory blood pressure and lipidomics profiles in mildly hypertensive subjects.


In a randomized, double-blind, placebo-controlled parallel group study, 89 mildly hypertensive subjects ingested, after a 1-month run-in period, a fermented milk drink with 5 mg per day of lactotripeptides during 3 months, and a milk drink with 50 mg per day of lactotripeptides for the following 3 months, or a placebo milk drink without lactotripeptides. Ambulatory blood pressure (24 h) was recorded at baseline and at the end of the intervention periods. Lipidomics profiles were characterized before and after the 6-month intervention.


After the second intervention period (50 mg per day of lactotripeptides), systolic and diastolic 24-h blood pressures decreased significantly in the peptide, but not in the placebo group. However, the treatment effects -2.6 mm Hg (95% confidence interval (CI): -5.7 to 0.4) in systolic and -1.3 mm Hg (95% CI: -3.4 to 0.8) in diastolic blood pressure did not reach statistic significance. Ingestion of 5 mg per day of lactotripeptides for 3 months did not lower blood pressure. The peptide group was dominated by decrease in multiple phospholipids (PL).


Ingestion of fermented milk with daily dose of 50 mg of lactotripeptides appears to lower elevated blood pressure slightly from the baseline, but not significantly compared with the placebo group and to induce significant decreases in multiple PL.

The blood pressure lowering effect of lactotripeptides and salt intake in 24-h ambulatory blood pressure measurements.


It is well known that the sour milk containing lactotripeptides has a blood pressure lowering effect. The aim of this study was to evaluate the blood pressure (BP) lowering effect of lactotripeptides by monitoring home blood pressure, 24-h ambulatory measurements (ABPM), and daily urinary salt excretion. A total of 30 volunteers were given 200 ml of sour milk twice a day for 8 weeks after a 1-week run-in period. This preparation contained the lactotripeptides valine-proline-proline 2.66 mg and isoleucine-proline-proline 1.38 mg. The study participants had daily measurements of urinary salt excretion determined by an electric salt sensor and home blood pressure for each week during the run-in period, before the 4-and 8-week time points. 24-h ABPM was measured at the end of each week. Mean systolic blood pressure (SBP) during night sleep including base BP at 4 and 8 weeks were significantly lower than baseline values. Mean SBP and diastolic blood pressure (DBP) during night sleep of the 22 participants who belonged to the criteria of hypertension by 24-h ABPM was significantly decreased at 4 and 8 weeks. The change in 24-h mean SBP significantly correlated with mean urinary salt excretion over the three measurement periods. The 22 hypertensive subjects without taking lactotripeptides did not show significant change of blood pressure during 24 hours at 4 and 8 weeks. Our study confirmed the BP lowering effect of lactotripeptides during night-time sleep and showed that a lower intake of salt may increase the BP lowering effect of lactotripeptides through 24 hours in hypertensive subjects.

Reference sources:

Amealpeptide data :


ACE Inhibitor effectiveness


Calpis Company


WRITE A REVIEW! Share your knowledge of this product. Be the first to WRITE A REVIEW »

Browse for more products in the same category as this item:

Shop All Products
Shop by Health Concern > Cardiovascular Support
Shop by Health Concern > Cardiovascular Support > Blood Pressure & Circulatory Support
Shop by Health Concern > Workout Support
Shop by Health Concern